Cite
MLA Citation
P. Sharma et al.. “3LBA CheckMate 025: a randomized, open-label, phase III study of nivolumab (NIVO) versus everolimus (EVE) in advanced renal cell carcinoma (RCC).” European journal of cancer, vol. 51, n.d., pp. S708–. http://access.bl.uk/ark:/81055/vdc_100030687872.0x000051